Ulys, Llc - Net Worth and Insider Trading

Ulys, Llc Net Worth

The estimated net worth of Ulys, Llc is at least $16 Million dollars as of 2024-05-03. Ulys, Llc is the 10% Owner of Lexicon Pharmaceuticals Inc and owns about 9,564,159 shares of Lexicon Pharmaceuticals Inc (LXRX) stock worth over $16 Million. Details can be seen in Ulys, Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ulys, Llc has not made any transactions after 2009-10-15 and currently still holds the listed stock(s).

Transaction Summary of Ulys, Llc

To

Ulys, Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ulys, Llc owns 3 companies in total, including Lexicon Pharmaceuticals Inc (LXRX) , Agenus Inc (AGEN) , and eHealth Inc (EHTH) .

Click here to see the complete history of Ulys, Llc’s form 4 insider trades.

Insider Ownership Summary of Ulys, Llc

Ticker Comapny Transaction Date Type of Owner
LXRX Lexicon Pharmaceuticals Inc 2022-08-01 director & 10 percent owner
AGEN Agenus Inc 2008-05-10 10 percent owner
EHTH eHealth Inc 2006-10-12 10 percent owner

Ulys, Llc Latest Holdings Summary

Ulys, Llc currently owns a total of 1 stock. Ulys, Llc owns 9,564,159 shares of Lexicon Pharmaceuticals Inc (LXRX) as of October 15, 2009, with a value of $16 Million.

Latest Holdings of Ulys, Llc

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
LXRX Lexicon Pharmaceuticals Inc 2009-10-15 9,564,159 1.71 16,306,891

Holding Weightings of Ulys, Llc


Ulys, Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Ulys, Llc has made a total of 0 transactions in Lexicon Pharmaceuticals Inc (LXRX) over the past 5 years. The most-recent trade in Lexicon Pharmaceuticals Inc is the acquisition of 2,207,876 shares on October 15, 2009, which cost Ulys, Llc around $23 Million.

Insider Trading History of Ulys, Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ulys, Llc Trading Performance

GuruFocus tracks the stock performance after each of Ulys, Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ulys, Llc is 25.74%. GuruFocus also compares Ulys, Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ulys, Llc within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Ulys, Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Ulys, Llc

Average Return

Average return per transaction

Outperforming Transactions

1 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 0.89
Relative Return to S&P 500(%) 0.5

Ulys, Llc Ownership Network

Ownership Network List of Ulys, Llc

No Data

Ownership Network Relation of Ulys, Llc


Ulys, Llc Owned Company Details

What does Lexicon Pharmaceuticals Inc do?

Who are the key executives at Lexicon Pharmaceuticals Inc?

Ulys, Llc is the director & 10 percent owner of Lexicon Pharmaceuticals Inc. Other key executives at Lexicon Pharmaceuticals Inc include director & President and CEO Lonnel Coats , director & 10 percent owner Raymond Debbane , and SVP & Chief Commercial Officer Thomas Garner .

Lexicon Pharmaceuticals Inc (LXRX) Insider Trades Summary

Over the past 18 months, Ulys, Llc made no insider transaction in Lexicon Pharmaceuticals Inc (LXRX). Other recent insider transactions involving Lexicon Pharmaceuticals Inc (LXRX) include a net purchase of 170,000 shares made by Lonnel Coats , a net purchase of 22,000 shares made by Jeffrey L Wade , and a net purchase of 16,000 shares made by Wendy Mcdermott .

In summary, during the past 3 months, insiders sold 0 shares of Lexicon Pharmaceuticals Inc (LXRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Lexicon Pharmaceuticals Inc (LXRX) were sold and 29,183,050 shares were bought by its insiders, resulting in a net purchase of 29,183,050 shares.

Lexicon Pharmaceuticals Inc (LXRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Lexicon Pharmaceuticals Inc Insider Transactions

No Available Data

Ulys, Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Ulys, Llc. You might contact Ulys, Llc via mailing address: C/o The Invus Group, Llc, 750 Lexington Avenue, 30th Floor, New York Ny 10022.

Discussions on Ulys, Llc

No discussions yet.